Michael Hoff’s Post

Key takeaways: 🔹 Abbott’s Aveir DR leadless pacemaker, the world’s very first dual-chamber pacing solution of its kind, is associated with a “reliable” performance after six months, according to new data published in Heart Rhythm.[1] 🔷 The Aveir DR system includes both an atrial leadless pacemaker (ALP) and a ventricular leadless pacemaker (VLP). The two devices were designed to communicate with one another as needed, helping patients with abnormal heart rhythms receive the care they need at any given time. 🔹 The U.S. Food and Drug Administration (FDA) approved the new-look device in July 2023, making leadless pacing available to a much wider patient population. While single-chamber leadless pacing has been around for several years, most bradycardia patients require dual-chamber pacing.

💉Penumbra, Inc. launches latest CAVT technology to rapidly remove blood clots Lightning Flash 2.0 is the next-generation computer-assisted vacuum thrombectomy (CAVT) system to remove venous thrombus and treat pulmonary emboli (PE). The next-gen CAVT system features advanced Lightning Flash algorithms designed for increased speed and sensitivity to thrombus and blood flow. Together with Penumbra, Inc.’s novel catheter technology, the system will help physicians better navigate through complex anatomy and deliver superior clot removal with minimal blood loss. Penumbra, Inc. FSIR chief medical officer James F. Benenati, M.D., FSIR said: “Based on what we’ve seen in the initial launch, Lightning Flash 2.0 has significantly improved procedure time by shortening the aspiration time. It has also shown reductions in blood removed during aspiration. “These advantages can improve patient safety, provide better outcomes for the patients and streamline efficiency for physicians treating the patients. “As adoption of thrombectomy becomes more widespread, Lightning Flash 2.0 will provide physicians with the confidence that CAVT is a valuable frontline option.” Read more online: https://lnkd.in/eAKaenfB 📰 Follow Medical Device Developments to receive the latest medical device news daily and to subscribe to our weekly newsletter #MedicalDeviceDevelopments #penumbra #bloodclots

Key takeaways: 6 months is not a long time 🥸, however this news is encouraging 😁 🔹 Abbott’s Aveir DR leadless pacemaker, the world’s very first dual-chamber pacing solution of its kind, is associated with a “reliable” performance after six months, according to new data published in Heart Rhythm.[1] 🔷 The Aveir DR system includes both an atrial leadless pacemaker (ALP) and a ventricular leadless pacemaker (VLP). The two devices were designed to communicate with one another as needed, helping patients with abnormal heart rhythms receive the care they need at any given time. 🔹 The U.S. Food and Drug Administration (FDA) approved the new-look device in July 2023, making leadless pacing available to a much wider patient population. While single-chamber leadless pacing has been around for several years, most bradycardia patients require dual-chamber pacing.

What can VABYSMO do for your wet AMD patients? We spoke to Dr. Caesar Luo (Bay Area Retina Associates), who describes the difference VABYSMO has made to Caroleve, one of his patients living with wet AMD: “Previously, Caroleve would require injections every 4–5 weeks to control her fluid. With VABYSMO, 𝐬𝐡𝐞 𝐡𝐚𝐬 𝐠𝐨𝐧𝐞 𝐟𝐫𝐨𝐦 𝐧𝐞𝐞𝐝𝐢𝐧𝐠 𝐚𝐧 𝐢𝐧𝐣𝐞𝐜𝐭𝐢𝐨𝐧 𝐞𝐯𝐞𝐫𝐲 𝐦𝐨𝐧𝐭𝐡 𝐭𝐨 𝐣𝐮𝐬𝐭 𝟒 𝐭𝐢𝐦𝐞𝐬 𝐚 𝐲𝐞𝐚𝐫.* If we can maintain excellent vision with fewer injections, 𝐭𝐡𝐚𝐭 𝐢𝐬 𝐚 𝐰𝐢𝐧 𝐟𝐨𝐫 𝐨𝐮𝐫 𝐩𝐚𝐭𝐢𝐞𝐧𝐭𝐬. For Caroleve, the ability to control her wet #amd with fewer treatments has been a benefit.” Watch Caroleve’s story below to learn about her experience with VABYSMO. Individual results may vary. *nAMD dosing: 4 monthly loading doses followed by OCT and visual acuity evaluations 8 and 12 weeks later to inform Q16W (weeks 28 and 44), Q12W (weeks 24, 36, and 48), Q8W (weeks 20, 28, 36, and 44), or Q4W (no added benefit) dosing. Read the full Prescribing Information here: bit.ly/VABPI Intended for US healthcare professionals only.

Did you hear?! 🎺 On Nov 14th, the Centers for Medicare & Medicaid Services released their final Skin Substitute Grafts/Cellular & Tissue-Based Products Local Coverage Determination (LCD) to include vascular assessments (such as tissue oxygenation), as part of the standard of care! THIS. IS. HUGE. A groundbreaking elevation of the Standard of Care! So, what does this mean for clinicians in the US who incorporate skin subs & CTPs into their practice? CMS has stated that vascular evaluation is vital for all patients with DFUs or VLUs via an ‘objective, non-invasive measure of perfusion/oxygenation.' This policy will come into effect on February 12th, 2025 — and MIMOSA is ready to help! Our MIMOSA Pro device is the only vascular assessment tool that combines tissue oxygenation, thermography, wound area reduction, and high-resolution digital imaging into a single, pocket-sized device. 4 insights, 1 device! This innovation allows clinicians to make rapid, data-driven decisions at the point of care — ensuring you make the right decision, for the right patient, at the right time! See MIMOSA for yourself at 👉 bit.ly/demo-mimosa. Our team is ready to help train & onboard your team as efficiently as possible! . . . #StandardOfCare #GameChanger #WoundCare #SkinSubs #SkinSubstitutions #WoundManagement #SkinImagingPlatform 

"I've got my life back." Dianne's life changed when she received her Inceptiv™ SCS implant. After finding relief from chronic back pain she says, "I feel10 years younger". Hear her story and learn how Inceptiv™ SCS can help patients enjoy greater freedom with consistent therapy that is automatic, responsive, and seamless. In a recent study, 9 out of 10 patients preferred using the Inceptiv™ closed-loop algorithm over fixed-output stimulation.(1) Inceptiv™ SCS is the most advanced spinal cord stimulation (SCS) system with closed-loop technology bringing patients pain relief that's in tune with their lives. More consistent therapy = more time for life. Go to Medtronic.com/Inceptiv to learn more. See risk information: https://bit.ly/4dlG6cQ #MDTPainInterventional #PatientFirst #InceptivSCS #ClosedLoopTechnology #MedtronicSCS #ClosedLoop #SCS #SpinalCordStimulation #ECAP 1. ECHO MAC Final Clinical Study Report V1.0 2021-08-18.

Penumbra, Inc. Revolutionizes Clot Removal with Lightning Flash 2.0 Exciting news in the world of cardiovascular care! Penumbra, a leading medical device company, has announced the FDA approval and commercialization of its latest innovation, the Lightning Flash 2.0 system. Lightning Flash 2.0 is the next-generation computer-assisted vacuum thrombectomy (CAVT) system designed to rapidly remove venous thrombus and treat pulmonary emboli (PE). Featuring advanced algorithms for increased speed and sensitivity, this system, combined with Penumbra's novel catheter technology, empowers physicians to navigate complex anatomy and deliver superior clot removal with minimal blood loss. According to Penumbra's FSIR chief medical officer, James F. Benenati, M.D., FSIR, "Lightning Flash 2.0 has significantly improved procedure time by shortening the aspiration time and shown reductions in blood removed during aspiration. These advantages can improve patient safety, provide better outcomes, and streamline efficiency for physicians."As the only computer-assisted mechanical thrombectomy systems currently available in the US, Penumbra's Lightning family of products continues to push the boundaries of cardiovascular care. With the launch of Lightning Flash 2.0, the company reaffirms its commitment to advancing patient care and ensuring more individuals can benefit from this transformative technology. https://lnkd.in/eAKaenfB Be sure to follow Practical Patient Care on LinkedIn for more industry news and insights. #PracticalPatientCare #MedicalDevices #CardiovascularCare #ThrombectomyInnovation

How does #IRRAflow facilitate fluid exchange during patient treatment?   With its use of a patented dual-lumen catheter design, IRRAflow allows the user to transition from passive drainage to a therapeutic treatment with active fluid management. Utilizing this dual-lumen design enables periodic flushing of the catheter tip.   Visit www.irraflow.com to learn more about active fluid exchange and how it can be integrated into clinical practice.   #medicaldevice #healthcare #medtech #criticalcare #medicalinnovation #neurocriticalcare #irras #irraflowfirst

💖 Medtronic announces positive long-term results of Aurora EV-ICD system The Medtronic EV ICD system is an implantable defibrillator designed to mitigate certain risks associated with traditional transvenous implantable cardioverter-defibrillators (ICDs). Its lead is positioned outside the heart and veins, beneath the breastbone using a minimally invasive approach. The system provides anti-tachycardia pacing (ATP) and pause prevention pacing, and it is similar in size, shape, and battery life to traditional transvenous ICDs. Read more online: https://lnkd.in/exVcmFnZ 📰 Follow Medical Device Developments to receive the latest medical device news daily and to subscribe to our weekly newsletter #MedicalDeviceDevelopments #medicaldevices #medicalmanufacturing

For too long, blood transfusions were considered a go-to solution for severe injuries or complex surgical procedures. This long-standing practice, however, is not without flaws. Studies indicate that a significant portion of these transfusions -up to 55%- might be unnecessary, posing avoidable risks to patients and driving up healthcare costs.  (https://lnkd.in/eMEHJ-8m) ProCell's Sponge Blood Recovery Unit (SBRU) can reduce transfusions by replacing the outdated, manual activity of hand-wringing blood-laden surgical sponges with an automated, more efficient blood collection process. One study showed the use of ProCell® had an average reduction in LDH of 37% (LDH is a marker for hemolysis). Thinking blood salvage? Think ProCell®